.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,772,325

« Back to Dashboard

Details for Patent: 8,772,325

Title:Compounds as opioid receptor modulators
Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Inventor(s): Breslin; Henry J. (Lansdale, PA), Cai; Chaozhong (North Wales, PA), He; Wei (Audubon, PA), Kavash; Robert W. (Glenside, PA)
Assignee: Janssen Pharmaceutica, N.V. (Beerse, BE)
Filing Date:Oct 03, 2013
Application Number:14/045,008
Claims:1. A method for treating pain or gastrointestinal disorder, wherein said pain is centrally mediated pain, peripherally mediated pain, structural or soft tissue injury related pain, pain related to inflammation, progressive disease related pain, neuropathic pain, acute pain, or chronic pain, and wherein said gastrointestinal disorder is ulcerative colitis, Crohn's disease, diarrhea-predominant irritable bowel syndrome, or alternating irritable bowel syndrome, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound having the structure: ##STR00045## or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein said compound has the structure: ##STR00046##

3. The method according to claim 2, wherein said compound has the structure: ##STR00047##

4. The method according to claim 2, wherein said compound has the structure: ##STR00048##

5. The method according to claim 2, wherein said compound has the structure: ##STR00049##

6. The method according to claim 1, comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable salt of said compound.

7. The method according to claim 6, wherein the salt is a hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic, or trifluoroacetic acid salt.

8. The method according to claim 6, wherein the salt is a benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc salt.

9. The method according to claim 1, wherein the chronic pain is selected from the group consisting of neuropathic pain conditions, diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, post-stroke pain syndromes and cluster or migraine headaches.

10. The method of claim 1, wherein the method is for treating centrally mediated pain.

11. The method according to claim 1, wherein the method is for treating peripherally mediated pain.

12. The method according to claim 1, wherein the method is for treating structural or soft tissue injury related pain.

13. The method according to claim 1, wherein the method is for treating pain related to inflammation.

14. The method according to claim 1, wherein the method is for treating progressive disease related pain.

15. The method according to claim 1, wherein the method is for treating neuropathic pain.

16. The method according to claim 1, wherein the method is for treating acute pain.

17. The method according to claim 1, wherein the method is for treating chronic pain.

18. The method according to claim 17, wherein the chronic pain is selected from the group consisting of neuropathic pain conditions, diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, post-stroke pain syndromes and cluster or migraine headaches.

19. The method according to claim 1, wherein the method is for treating ulcerative colitis.

20. The method according to claim 1, wherein the method is for treating Crohn's disease.

21. The method according to claim 1, wherein the method is for treating diarrhea-predominant irritable bowel syndrome.

22. The method according to claim 1, wherein the method is for treating alternating irritable bowel syndrome.

23. A method for treating diarrhea-predominant irritable bowel syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound having the structure: ##STR00050## or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc